Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Short Interest Down 37.4% in June

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Get Free Report) was the target of a significant decrease in short interest in the month of June. As of June 15th, there was short interest totaling 1,609,679 shares, a decrease of 37.4% from the May 31st total of 2,572,499 shares. Based on an average daily volume of 1,385,421 shares, the days-to-cover ratio is presently 1.2 days. Approximately 1.1% of the shares of the stock are sold short.

Analysts Set New Price Targets

Several brokerages have recently commented on CNTA. Guggenheim cut shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Monday, April 20th. Needham & Company LLC cut Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Stephens lowered Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Finally, Leerink Partners downgraded Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and upped their price objective for the stock from $36.00 to $40.00 in a research report on Wednesday, April 1st. Four research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $41.33.

Get Centessa Pharmaceuticals alerts:

Get Our Latest Analysis on CNTA

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in CNTA. Avoro Capital Advisors LLC increased its holdings in Centessa Pharmaceuticals by 34.7% in the fourth quarter. Avoro Capital Advisors LLC now owns 14,555,555 shares of the company’s stock valued at $364,034,000 after purchasing an additional 3,747,475 shares during the period. Adage Capital Partners GP L.L.C. increased its stake in shares of Centessa Pharmaceuticals by 12.4% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 11,281,741 shares of the company’s stock valued at $282,156,000 after buying an additional 1,246,741 shares during the period. Farallon Capital Management LLC raised its position in shares of Centessa Pharmaceuticals by 24.1% during the fourth quarter. Farallon Capital Management LLC now owns 5,377,068 shares of the company’s stock worth $134,480,000 after acquiring an additional 1,045,750 shares during the last quarter. Perceptive Advisors LLC lifted its stake in shares of Centessa Pharmaceuticals by 80.2% in the first quarter. Perceptive Advisors LLC now owns 5,258,903 shares of the company’s stock worth $208,884,000 after acquiring an additional 2,341,269 shares during the period. Finally, Siren L.L.C. lifted its stake in shares of Centessa Pharmaceuticals by 24.8% in the fourth quarter. Siren L.L.C. now owns 4,027,517 shares of the company’s stock worth $100,728,000 after acquiring an additional 800,000 shares during the period. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Price Performance

Shares of CNTA remained flat at $40.50 during trading hours on Thursday. Centessa Pharmaceuticals has a 1-year low of $12.74 and a 1-year high of $40.56. The firm has a market cap of $6.27 billion, a PE ratio of -22.63 and a beta of 1.11. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.23. The stock’s 50-day moving average is $39.81 and its 200-day moving average is $31.92.

Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). As a group, analysts forecast that Centessa Pharmaceuticals will post -1.65 EPS for the current fiscal year.

About Centessa Pharmaceuticals

(Get Free Report)

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.

Featured Articles

• Five stocks we like better than Centessa Pharmaceuticals
• Shorting the Grid: Bloom Energy’s $25B AI Power Play
• SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
• Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
• 3 Dividend ETFs Built for Stability in a Volatile Market

Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.